Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery
about
Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90Mechanisms of Hsp90 regulationC-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balancesLPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung.Emergence of protein kinase CK2 as a key target in cancer therapyAntitumoral activity of allosteric inhibitors of protein kinase CK2.Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degenerationTargeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.Post-translational modifications of Hsp90 and their contributions to chaperone regulationPhosphorylation of CRN2 by CK2 regulates F-actin and Arp2/3 interaction and inhibits cell migration.Conformational processing of oncogenic v-Src kinase by the molecular chaperone Hsp90.Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 ExpressionSingle-step inline hydroxyapatite enrichment facilitates identification and quantitation of phosphopeptides from mass-limited proteomes with MudPITDual action antifungal small molecule modulates multidrug efflux and TOR signalingBIRC6 mediates imatinib resistance independently of Mcl-1.Phosphorylated and unphosphorylated serine 13 of CDC37 stabilize distinct interactions between its client and HSP90 binding domains.Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.Nuclear localization of the CK2α-subunit correlates with poor prognosis in clear cell renal cell carcinoma.D11-Mediated Inhibition of Protein Kinase CK2 Impairs HIF-1α-Mediated Signaling in Human Glioblastoma Cells.Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.Targeting CK2-driven non-oncogene addiction in B-cell tumors.The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment.Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.CK2-An Emerging Target for Neurological and Psychiatric Disorders.Alternative approaches to Hsp90 modulation for the treatment of cancer.Stimulation of CK2-dependent Grp94 phosphorylation by the nuclear localization signal peptide.Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors.How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches.Regulatory Mechanisms of Hsp90.Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy.The p23 co-chaperone protein is a novel substrate of CK2 in Arabidopsis.Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.Protein kinase CK2 regulates redox homeostasis through NF-κB and Bcl-xL in cardiomyoblasts.Modulation of transcriptional mineralocorticoid receptor activity by casein kinase 2.Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects.
P2860
Q24336102-10720058-613C-4350-9695-663F51FD7150Q26741834-6A3DF17E-A79F-4700-BEFB-DF95149D204AQ28271643-C780F604-E9F8-4A4D-8F90-DDCC6F72DC40Q29347538-0895A946-6E17-44FE-92CC-ABE8442CACDCQ34046848-C3CE546C-BEC9-4D04-A777-425DA5B5DBABQ34106499-E32E0386-3635-4418-B085-0213D739232BQ34380573-2A7433D7-8F2D-45EE-BEE5-4F89E9D50771Q34915636-673D4233-BD8C-4DB6-A7AD-594992BE6C10Q35005510-4B4F81DA-1204-4B40-A876-ECC484D11BF5Q35096710-B1FEAB3B-C0B0-438F-920F-5E923DE63578Q35500311-A77400BA-A880-4756-8683-14311000EECBQ35581165-43F6A172-49B4-4EFB-AE33-8E17271FAE74Q35712790-A3412D88-6579-477C-83FA-953BC6960012Q35796269-440D6D0D-38C9-4F59-B94B-D1ED3670664AQ35800838-C66CF6FD-A9CD-4A81-BFE0-5A0D2274A014Q35860589-490A2702-3BB2-44BF-812D-3A9E83960E6FQ36002714-4581CC53-65DF-4AF8-BEDD-2497E67F08E4Q36116026-43AA81A7-5164-467B-A5CF-3440D1A1D341Q36375641-6EA98796-1B2B-44BD-A5B2-83932AB7E854Q36824214-3CBEA0A2-CBBA-4147-8BF6-B0EA864538C2Q37599312-41EC32D0-FD5F-411A-BF4C-A4CC42547A31Q37702141-3D0B49B5-4B03-4969-804F-8932D0BD8ED2Q37731308-FBE5FA74-0DDA-484A-9385-B89B2FB13A2FQ38111801-DA271DF4-C000-4781-98D0-359B1CF3AEC3Q38797342-63685218-4729-4E03-9351-377CDC060537Q38826790-08F9851C-249E-4AEA-9045-32426594F623Q38897744-027B731A-2B47-4B27-91E5-E0DC624D3D3CQ39076762-1AADA376-9B5D-42DF-8D50-ED77A2808A90Q39103704-F19AEB98-45AA-40F9-B21D-5EDEAE2FEB12Q39510526-F5EFD217-CB0F-44F2-B301-BD3A28A3B64EQ39551009-58649FE6-30B6-4D0F-BC86-33379F3421C4Q41596905-D85D0020-2D10-4B5B-BA16-8717EA981E8FQ42146382-C1631ABF-C8F5-4C9B-978C-121B215B3B43Q42284390-2DBF2419-A515-46B9-A270-CE7AD7791486Q42481944-7305248D-1188-4283-A782-3D9894A50D03Q44000767-625EC935-8604-48A8-A4D6-ED4A04596903Q45997277-7BEBDF5C-750C-46CB-BE38-00C7ECF961D7Q46353725-1B83CE8D-61B6-43AD-9370-A5CD1767D1DAQ47096252-59A5991F-8782-4738-BDDE-C1DB5BF5A627Q52298994-0D76F626-6988-41E6-9DE2-857747403E46
P2860
Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@ast
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en-gb
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@nl
type
label
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@ast
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en-gb
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@nl
prefLabel
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@ast
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en-gb
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@nl
P921
P3181
P1476
Protein kinase CK2 in health a ...... the Hsp90 chaperone machinery
@en
P2093
P2888
P304
P3181
P356
10.1007/S00018-009-9152-0
P407
P577
2009-06-01T00:00:00Z
P6179
1052748055